Shire Pharmaceuticals
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles about Shire Pharmaceuticals
-
Shire Pharmaceuticals Announces Award Recipients for 2013 US ADHD Scholarship Program
7/19/2013
-
Shire plc Ups Headcount Despite Takeover Rumors
6/10/2013
-
A Jilted Shire Pharmaceuticals Exec, Age Discrimination and a Federal Probe?
5/31/2013
-
Shire plc to Present at the Deutsche Bank 38th Annual Health Care Conference
5/30/2013
-
Shire plc Reverses Decision to Move Headquarters
5/30/2013
-
Shire plc to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychological Association Annual Meeting
5/17/2013
-
Shire plc Wins Patent Trial Against Watson Pharmaceuticals, Inc. Concerning LIALDA®
5/9/2013
-
Nimbus Discovery Announces Agreement With Shire plc to Co-Develop Therapies for Rare Diseases
5/8/2013
-
Shire plc Release: New Chief Executive Reports Q1 Results and Sets out Strategy for Growth
5/2/2013
-
AGA Research Foundation Receives $200K Gift From Shire Pharmaceuticals
4/24/2013
-
Shire plc Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
4/9/2013
-
Shire plc Boosts Eye Business With $160 Million SARcode Buy
3/25/2013
-
Shire plc Boosts Rare Diseases Business by Buying Premacure
3/12/2013
-
Shire plc's New Chief Said to Eye Two to Three Acquisitions
2/21/2013
-
Shire plc to Forest Laboratories, Inc. on Deal List for AstraZeneca PLC: Real M&A
2/14/2013
-
Shire plc Delivers Strong 2012 Results and Reiterates Confidence in 2013
2/14/2013
-
Shire plc Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients With Epidermolysis Bullosa
2/8/2013
-
IMPAX Laboratories, Inc. Settles All Adderall XR Litigation With Shire Pharmaceuticals
2/8/2013
-
Shire plcTakes $57.5 Million Charge to Settle Marketing Probe
2/4/2013
-
Shire plc Rises on AstraZeneca PLC Bid Talk: Traders
1/17/2013